Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.
His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.
His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.
Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, Perindopril and Sovaldi™ and due diligence work to support acquisitions (eg New River Pharmaceuticals and Renovo, and IPO's (eg Redx and NuCana plc), and private equity investment funding (eg OriBiotech).
In the non-pharmaceutical area, he has been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's two Nobel Prize winners Geim and Novoselov.
Jonathan's clients include large and small companies, universities and government organisations.
Cert in IP Law Queen Mary, London
C. Chem, FRSC
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
HGF Patent Attorney Dr Robert Weinert-Aplin is attending and speaking at the Manufacturing & Supply Chain Conference on 10th March 2022 in Milton Keynes, UK. The Manufacturing & Supply Chain …Event details
HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …Read article
With news that the Austrian parliament has ratified the Protocol on the provisional application of the Agreement on a Unified Patent Court on 2 December 2021, the Unified Patent Court …Read article
One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.